Research Topics

Stephan Brecht

Affiliation: Boehringer Ingelheim

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial
Stephan Brecht
Boehringer Ingelheim GmbH, Ingelheim, Germany
J Clin Psychiatry 68:1707-16. 2007
Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial
Stephan Brecht
CDep Medical Affairs, Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein, Ingelheim, Germany
J Clin Psychiatry 72:1086-94. 2011
Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder
Stephan Brecht
Boehringer Ingelheim GmbH, Ingelheim, Germany
Int Clin Psychopharmacol 23:317-24. 2008

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial
Stephan Brecht
Boehringer Ingelheim GmbH, Ingelheim, Germany
J Clin Psychiatry 68:1707-16. 2007
..This study evaluated the efficacy and safety of duloxetine in the treatment of patients with moderate pain associated with depression...
Efficacy and safety of duloxetine 60 mg and 120 mg daily in patients hospitalized for severe depression: a double-blind randomized trial
Stephan Brecht
CDep Medical Affairs, Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein, Ingelheim, Germany
J Clin Psychiatry 72:1086-94. 2011
..To assess whether hospitalized patients with severe depression and potential suicidal ideation/behavior have earlier and better response to duloxetine 120 mg daily than 60 mg daily...
Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder
Stephan Brecht
Boehringer Ingelheim GmbH, Ingelheim, Germany
Int Clin Psychopharmacol 23:317-24. 2008
....